CN101565752B - 肿瘤多药耐药相关基因的荧光定量pcr检测试剂盒 - Google Patents
肿瘤多药耐药相关基因的荧光定量pcr检测试剂盒 Download PDFInfo
- Publication number
- CN101565752B CN101565752B CN2009101039826A CN200910103982A CN101565752B CN 101565752 B CN101565752 B CN 101565752B CN 2009101039826 A CN2009101039826 A CN 2009101039826A CN 200910103982 A CN200910103982 A CN 200910103982A CN 101565752 B CN101565752 B CN 101565752B
- Authority
- CN
- China
- Prior art keywords
- gene
- mrp1
- mdr1
- lrp
- fluorescent probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 37
- 108700041567 MDR Genes Proteins 0.000 title claims abstract description 20
- 238000003753 real-time PCR Methods 0.000 title claims abstract description 14
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 37
- 101150112014 Gapdh gene Proteins 0.000 claims abstract description 29
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims abstract description 28
- 101150000411 lrp gene Proteins 0.000 claims abstract description 24
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims abstract description 19
- 238000011144 upstream manufacturing Methods 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 24
- 101150017517 MRP1 gene Proteins 0.000 claims description 19
- 238000013016 damping Methods 0.000 claims description 18
- 239000012530 fluid Substances 0.000 claims description 18
- 101150066553 MDR1 gene Proteins 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 10
- 102100034343 Integrase Human genes 0.000 claims description 7
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 abstract description 25
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 abstract description 18
- 230000036457 multidrug resistance Effects 0.000 abstract description 14
- 239000002299 complementary DNA Substances 0.000 abstract description 10
- 239000000523 sample Substances 0.000 abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 101001039256 Caenorhabditis elegans Low-density lipoprotein receptor-related protein Proteins 0.000 abstract 3
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 abstract 3
- 101001030069 Homo sapiens Major vault protein Proteins 0.000 abstract 3
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 abstract 3
- 101000738769 Homo sapiens Receptor-type tyrosine-protein phosphatase alpha Proteins 0.000 abstract 3
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 abstract 3
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 238000010839 reverse transcription Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000008521 reorganization Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000003939 Membrane transport proteins Human genes 0.000 description 2
- 108090000301 Membrane transport proteins Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 150000001454 anthracenes Chemical class 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 201000005619 esophageal carcinoma Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 102000045449 ABC-type glutathione S-conjugate transporter activity proteins Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- -1 carboxyl tetramethyl-rhodamine Chemical compound 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108010062890 glutathione transporter Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011396 initial chemotherapy Methods 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical class O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 101150062876 mrp gene Proteins 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101039826A CN101565752B (zh) | 2009-05-27 | 2009-05-27 | 肿瘤多药耐药相关基因的荧光定量pcr检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101039826A CN101565752B (zh) | 2009-05-27 | 2009-05-27 | 肿瘤多药耐药相关基因的荧光定量pcr检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101565752A CN101565752A (zh) | 2009-10-28 |
CN101565752B true CN101565752B (zh) | 2012-03-14 |
Family
ID=41282114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101039826A Expired - Fee Related CN101565752B (zh) | 2009-05-27 | 2009-05-27 | 肿瘤多药耐药相关基因的荧光定量pcr检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101565752B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012105644A (ja) * | 2010-10-28 | 2012-06-07 | Arkray Inc | 多型検出用プローブ、多型検出方法、薬効評価方法、および多型検出用キット |
CN105734152B (zh) * | 2016-04-20 | 2019-02-26 | 苏州吉诺瑞生物科技有限公司 | 检测人srpk2基因的表达水平的特异引物对及其应用 |
-
2009
- 2009-05-27 CN CN2009101039826A patent/CN101565752B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101565752A (zh) | 2009-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109790583B (zh) | 对肺腺癌亚型分型的方法 | |
CN102719525B (zh) | 用于检测eml4-alk融合基因突变的引物、探针及检测试剂盒 | |
AU2018210695A1 (en) | Molecular subtyping, prognosis, and treatment of bladder cancer | |
CN108949990B (zh) | 一种检测egfr基因突变的试剂盒及方法 | |
KR20150090246A (ko) | 암을 위한 분자 진단 테스트 | |
KR20140044341A (ko) | 암에 대한 분자적 진단 검사 | |
TW201013187A (en) | Molecular markers for lung and colorectal carcinomas | |
CN110199032A (zh) | 羟基类固醇17-β脱氢酶13(HSD17B13)变体及其用途 | |
US20190256930A1 (en) | Biomarkers for determining responsiveness to lsd1 inhibitors | |
CN109679957B (zh) | IncRNALNC_004208及其检测试剂在制备脑胶质瘤预后试剂中的应用 | |
CN105506158B (zh) | 长链非编码rna loc284454的应用方法 | |
CN115087749A (zh) | 用于通过分析循环肿瘤dna进行分子疾病评定的方法和*** | |
CN103695531A (zh) | Abcb1基因多态性焦磷酸测序方法及试剂盒 | |
CN101565752B (zh) | 肿瘤多药耐药相关基因的荧光定量pcr检测试剂盒 | |
WO2019178215A1 (en) | Methods and compositions for treating, prognosing, and diagnosing esophageal cancer | |
CN106048073B (zh) | 一种卵巢癌辅助诊断或者疗效预测用的生物标记物及其应用 | |
CN107988370B (zh) | 一种circRNA基因在制备诊断慢性粒细胞性白血病试剂中的应用 | |
KR20170058984A (ko) | 편평상피암에 대한 화학 방사선 요법의 유효성을 평가하기 위한 방법 | |
Zhang et al. | Bioinformatics analysis of breast cancer bone metastasis related gene-CXCR4 | |
CN106319043B (zh) | 长链非编码rna linc01420的应用方法 | |
CN104650214B (zh) | 肺动脉高压致病基因acvrl1突变位点及其应用 | |
CN114214430A (zh) | Nkg2a在检测小鼠人源肿瘤模型中人nk细胞中的应用 | |
CN110951877A (zh) | 用于检测mn1基因相对表达量的引物,探针 | |
CN105506131A (zh) | 检测人aeg-1基因表达量和相对表达量的引物对 | |
CN105911282A (zh) | 一种口腔癌特异性检测的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ZOU LIN Free format text: FORMER OWNER: ZHANG PENGHUI Effective date: 20100322 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zou Lin Inventor after: Zhang Penghui Inventor after: Tan Junjie Inventor before: Zhang Penghui |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG PENGHUI TO: ZOU LIN ZHANG PENGHUI TAN JUNJIE Free format text: CORRECT: ADDRESS; FROM: 400016 8-8, KANGDE LIVING SPACE OF 27 DEGREES, YIXUEYUAN ROAD, YUZHONG DISTRICT, CHONGQING CITY TO: 400015 NO.136, ZHONGSHAN 2ND ROAD, YUZHONG DISTRICT, CHONGQING CITY |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100322 Address after: 400015 No. two, No. 136, Zhongshan Road, Yuzhong District, Chongqing Applicant after: Zou Lin Address before: 400016 Chongqing Yuzhong District Medical College Road Kant 27 degrees living space 8-8 Applicant before: Zhang Penghui |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHILDREN S HOSPITAL ATTACHED TO CHONGQING MEDICAL Free format text: FORMER OWNER: ZOU LIN Effective date: 20120808 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120808 Address after: 400015 No. two, No. 136, Zhongshan Road, Yuzhong District, Chongqing Patentee after: Children's Hospital Affiliated to Medical University of Chongqing Address before: 400015 No. two, No. 136, Zhongshan Road, Yuzhong District, Chongqing Patentee before: Zou Lin |
|
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zou Lin Inventor after: Jin Xianqing Inventor after: Luo Qing Inventor after: Zhang Penghui Inventor after: Tan Junjie Inventor after: Wang Shan Inventor before: Zou Lin Inventor before: Zhang Penghui Inventor before: Tan Junjie |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZOU LIN ZHANG PENGHUI TAN JUNJIE TO: ZOU LIN JIN XIANQING LUO QING ZHANG PENGHUI TAN JUNJIE WANG SHAN |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120314 Termination date: 20150527 |
|
EXPY | Termination of patent right or utility model |